Kovitz Investment Group Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kovitz Investment Group Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Sell	33,137 -2,448	-7%	-$134K	0.04%	239
2026 Q1	$2.01M	Sell	35,585 -2,700	-7%	-$157K	0.05%	225
2025 Q4	$2.28M	Sell	38,285 -10,530	-22%	-$573K	0.05%	215
2025 Q3	$2.64M	Buy	+48,815	New	+$2.79M	0.01%	585
2025 Q1	–	Sell	-4,964	Closed	-$326K	–	1254
2024 Q4	$326K	Sell	4,964 -117	-2%	-$7.84K	﹤0.01%	1019
2024 Q3	$251K	Buy	5,081 +1,981	+64%	+$166K	﹤0.01%	904
2024 Q2	$255K	Buy	+3,100	New	+$258K	﹤0.01%	760

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Kovitz Investment Group Partners's BMRN Position: Q2 2026 in Review

Kovitz Investment Group Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 6.9% in Q2 2026, selling an estimated $134K and leaving 33,137 shares worth $1.9M. The position accounts for 0.04% of the portfolio, ranked #239.

Kovitz Investment Group Partners first reported a position in BMRN in Q2 2024 and has held it in 7 quarters since. The position peaked at $2.64M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Kovitz Investment Group Partners held 33,137 shares of BioMarin Pharmaceuticals worth $1.9M as of Q2 2026.
Kovitz Investment Group Partners sold 2,448 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $134K.
BioMarin Pharmaceuticals made up 0.04% of Kovitz Investment Group Partners's portfolio in Q2 2026, its #239 holding.
Kovitz Investment Group Partners first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
Kovitz Investment Group Partners's BioMarin Pharmaceuticals position peaked at $2.64M in Q3 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Kovitz Investment Group Partners's 13F filing for Q2 2026, filed 12 Aug 2026.